Work

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

Year: 2013

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(13)70465-0

Authors: Thomas E Hutson, Vladimir Lesovoy, Salman Al-Shukri, Viktor P Stus, Oleg N Lipatov, Angel H Bair, Brad Rosbrook, Connie Chen, Sinil Kim, Nicholas J Vogelzang

Institutions: Baylor University Medical Center, First Pavlov State Medical University of St. Petersburg, Republican Oncological Clinical Dispensary, Pfizer (United States), Comprehensive Cancer Centers of Nevada

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Pfizer, Memorial Sloan-Kettering Cancer Center

OpenAlex ID: W2103689170

FWCI: 19.87

Cites: 27

Cited by: 423

Related to: 10